
Aurobindo Pharma arm Eugia gets USFDA nod for Dasatinib tablets
(20 second reading) Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final USFDA approval to market Dasatinib Tablets in multiple strengths (20–140 mg). These tablets are equivalent to Sprycel by Bristol-Myers Squibb and are set to launch in Q1 FY2026. The drug targets a market worth $1.8 billion (as of Feb 2025, IQVIA MAT). This marks Eugia’s 181st ANDA approval, including nine tentative ones
Quicklinks